CervoMed Announces Presentation Of Biomarker Data From The AscenD-LB Phase 2a Trial And Preclinical Data Supporting Potential Of Neflamapimod In Tau-Mediated Disease At AD/PD 2024
CervoMed Announces Presentation Of Biomarker Data From The AscenD-LB Phase 2a Trial And Preclinical Data Supporting Potential Of Neflamapimod In Tau-Mediated Disease At AD/PD 2024
CervoMED 宣布在 2024 年 AD/PD 上公布来自 Ascend-LB 2a 期试验的生物标志物数据和支持奈弗拉匹莫德在陶介导疾病中的潜力的临床前数据
- Neflamapimod led to significant reduction compared to placebo in plasma levels of glial fibrillary acidic protein (GFAP)
-与安慰剂相比，奈弗拉匹莫德导致血浆胶质纤维酸性蛋白（GFAP）水平显著降低
- Neflamapimod effects on GFAP correlated to clinical outcomes assessed by CDR Sum of Boxes (CDR-SB)
- 奈弗拉匹莫德对 GFAP 的影响与 CDR Boxes Sum of Boxes (CDR-SB) 评估的临床结果相关
- Scientific collaborators from University College London (UCL) present data demonstrating neflamapimod improves axonal transport in a transgenic mouse model of frontotemporal dementia (FTD)
-伦敦大学学院（UCL）的科学合作者提供的数据表明，奈弗拉马莫德改善了额叶痴呆（FTD）转基因小鼠模型的轴突转移
BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced the presentation of biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies...
波士顿，2024年3月5日（GLOBE NEWSWIRE）——专注于开发脑退行性疾病治疗...
登录免费看全文
登录/注册